Psoriasis: omega-3 supplements ease symptoms in meta-analysis

  • Clark CCT & al.
  • Clin Rheumatol
  • 18 Feb 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A systematic review and meta-analysis suggest that supplementation with omega-3 polyunsaturated fatty acids (PUFA) is associated with beneficial clinical effects for patients with psoriasis.

Why this matters

  • Individual studies have yielded inconsistent results.

Key results

  • Omega-3 PUFA supplementation was associated with reduced Psoriasis Area and Severity Index (PASI) score compared with control (−1.58; P<.00001 standardized mean difference ci to>
  • Omega-3 PUFA supplementation was also associated with reduced erythema (−1.66 units; P=.0001; SMD, −1.55; 95% CI, −2.47 to −0.62) and scaling (weighted mean difference, −0.69; P=.02; SMD, −2.06; 95% CI, −3.66 to −0.46) compared with control.
  • Omega-3 PUFA supplementation was not significantly associated with improvements in percentage of total body surface area affected, desquamation, or infiltration (P>.05 for all).
  • Significant improvements in erythema, itching, and scaling were observed in the trials that used a higher dosage of omega-3 PUFA supplementation (≥1800 mg/day).

Study design

  • 560 patients with psoriasis from 10 studies were included in the meta-analysis.
  • Funding: None disclosed.

Limitations

  • Small sample sizes in included trials.
  • Heterogeneity between included studies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit